- SHRM appoints top depression researcher as new chief executive officer
- McIntyre established Canada’s first-ever center to provide rapid-onset treatments for individuals with mood disorders
- Champignon also announces appointment of new board member
Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a Canada-based company dedicated applying novel and natural treatment protocols with an emphasis on psychedelic medicine, has appointed one of the world’s top researchers on depression as its new chief executive officer (http://nnw.fm/M6qzI). In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus area for Champignon.
“My overarching aim as chief executive officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments,” McIntyre stated in a news release. “The clinical infrastructure, complementary asset base and human capital that Champignon has acquired leaves me very confident we will provide life-changing treatments for persons with depression, all the while contemporaneously rewarding our investor base.
“I have been honored as a professor of psychiatry and pharmacology at the University of Toronto, as well as a professor at universities across the United States and Asia and currently head the world’s largest clinical R&D network in depression,” McIntyre continued. “The Canadian Rapid Treatment Centre of Excellence [CRTCE], that I envisaged and successfully implemented, is the world’s first integrated clinical and R&D centre in ketamine and psychedelic-based treatments and is identified as the most influential scientific center for depression research.”
A professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, McIntyre also serves as executive director of the Brain and Cognition Discovery Foundation in Toronto; director and chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) in Chicago, Illinois.; professor and Nanshan scholar at Guangzhou Medical University; and adjunct professor at the College of Medicine at Korea University. McIntyre is also a clinical professor at the State University of New York (SUNY) Upstate Medical University, Syracuse, New York, and a clinical professor in the Department of Psychiatry and Neurosciences, at the University of California Riverside School of Medicine.
McIntyre has been named one of the World’s Most Influential Scientific Minds each year from 2014 to 2019 by Clarivate Analytics. He is renowned as one of the world’s most recognized psychiatrists in relation to mood disorders, and has garnered extensive experience collaborating with private-sector partners, including those in the pharmaceutical, insurance and health-care industries.
“We are extremely pleased and fortunate to be able to bring Dr. McIntyre aboard as CEO,” added Gareth Birdsall, who has been serving as Champignon CEO and will continue in his service as director of Champignon. “Dr. McIntyre is the world’s leading authority on depression and associated mood disorders, which is further crystalized by his foresight in founding Canada’s first integrated mood disorder treatment and integrated research center in the CRTCE. Dr. McIntyre’s clear ability to execute and his entrepreneurial nature, along with a demonstrated capacity to lead and delegate in dynamic and growing organizations, represent the skill sets that Champignon needs as it moves towards our North American clinic expansion and maturing novel drug discovery initiatives.”
In addition to the appointment of McIntyre, SHRM also announced that it had appointed Pat McCutcheon as a member of its board of directors (http://nnw.fm/MaT24). McCutcheon currently serves as CEO of MediPharm, a leading global cannabis company. McCutcheon founded MediPharm with the objective of building the first pure-play cannabis company focused solely on extraction and API manufacturing.
“I am excited to join the Board of Directors of Champignon given its leadership position with the only licensed operating ketamine clinic and integrated research centre of its kind in Canada,” said McCutcheon. “I look forward to working with the board and the company’s management team to advance Champignon’s clinical development and expansion program in the US and Canada. I also look forward to assisting the company with its plan to evaluate other assets and new partnerships that will expand its pipeline in the rapidly emerging ketamine and psilocybin for mental health industry that has demonstrated strong potential in a short period of time.”
Prior to his work at MediPharm, McCutcheon held top management roles with several large pharmaceutical companies, including Jansen Pharmaceuticals (Johnson & Johnson), Sanofi and Astra Zeneca, where he was directly responsible for launching a wide range of medical products.
“We are tremendously pleased to have Pat join the Champignon Board,” said Birdsall. “His extensive experience in commercial development across the pharmaceutical industry combined with direct experience operating and scaling highly profitable businesses further strengthens our board with expertise that will accelerate the expansion of our clinical footprint via the establishment of net new clinical entities, as well as industry partnerships for ketamine, psilocybin and MDMA.”
Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.
For more information, visit the company’s website at www.ChampignonBrands.com
NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://nnw.fm/SHRM
PsychedelicNewsWire (PNW) is a far-out information destination focused on (1) delivering the freshest headlines on psychedelics and ‘shrooms, (2) issuing PsychedelicNewsBreaks that are specially crafted to keep the grooviest investors in-the-know, (3) laying down the choicest enhancements for corporate news releases, (4) doing our public and private client-partners a solid with full-service distribution and social media services and (5) taking custom-built corporate communication solutions to the max. PNW has a totally awesome spot in the booming psychedelics space, and our ace team of journalists is always grinding to help our growing roster of clients reach a sizable audience of investors, consumers and media outlets. We’ve got a network of more than 5,000 key syndication outlets to help you deliver dy-no-mite visibility, recognition and content within the psychedelic industry. PsychedelicNewsWire (PNW) is where PSYCHEDELIC news, content and information converge.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.